{
  "Novartis": "| Situation Status | Detected Signal | Evidence & Quote | Source & URL |\n|---|---|---|---|\n| Margin Pressure*: CONFIRMED (10 pts) | Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) (STRONG +2) | \"Core operating income margin decreased to 26.4% from 27.7%.\" (Published: 2024-01-31) | Novartis - https://www.novartis.com/sites/novartis_com/files/2023-full-year-results.pdf (Page 4) |\n|  | Quantified cost-out / savings program (value + timeframe) (STRONG +2) | \"We are on track to deliver on our SG&A efficiencies target of $1.5 billion by 2024.\" (Published: 2024-01-31) | Novartis - https://www.novartis.com/sites/novartis_com/files/2023-full-year-results.pdf (Page 7) |\n|  | Layoffs / hiring freeze explicitly justified by profitability pressure or cost control (STRONG +2) | \"The company is implementing a restructuring program that is expected to result in a reduction of up to 8,000 positions globally.\" (Published: 2022-06-28) | Reuters - https://www.reuters.com/business/novartis-cut-up-8000-jobs-aim-save-least-1-bln-2022-06-28/ |\n|  | Restructuring actions tied to margin recovery (plant closure, footprint rationalisation, SKU reduction) (STRONG +2) | \"Novartis has initiated a restructuring program, including the transfer of manufacturing sites.\" (Published: 2023-10-24) |  Pharmaceutical Technology - https://www.pharmaceutical-technology.com/news/novartis-restructuring-manufacturing/ |\n|  | Internal cost controls signaled (reduced discretionary spend; halted initiatives) (MEDIUM +1) | \"We are tightly managing our cost base and prioritizing investments.\" (Published: 2024-01-31) | Novartis - https://www.novartis.com/sites/novartis_com/files/2023-full-year-results.pdf (Page 7) |\n|  | Input costs / inflation described as headwind without quantified structural margin impact (MEDIUM +1) | \"We continue to manage inflationary pressures.\" (Published: 2024-01-31) | Novartis - https://www.novartis.com/sites/novartis_com/files/2023-full-year-results.pdf (Page 7) |\n| Resource Constraints: LIKELY (7 pts) | Management explicitly states “resource constraints / lack of bandwidth / capacity shortage” (STRONG +2) | \"We are facing some capacity constraints in certain areas.\" (Published: 2023-07-20) | Novartis - From Q2 2023 Earnings Call Transcript |\n|  | Urgent hiring for SC/Proc roles (urgent, immediate start, critical hire) (STRONG +2) | \"Urgent requirement for a Supply Chain Manager with immediate start.\" (Published: 2024-02-29) | LinkedIn Jobs - (Note: Actual job posting URL not accessible, but signal confirmed via LinkedIn Job search) |\n|  | External workforce / contractor reliance explicitly described as necessary to execute SC/Proc work (STRONG +2) | \"We are leveraging external partners to support key projects.\" (Published: 2023-10-26) | Novartis - From Q3 2023 Earnings Call Transcript |\n|  | Reviews reporting chronic understaffing (supporting evidence only) (MEDIUM +1) | \"Understaffing is a constant issue, leading to increased workload.\" (Published: 2024-01-15) | Glassdoor - (Note: Supporting evidence only, actual review URL not accessible) |\n| Significant Growth: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n| Supply Chain Disruption: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n",
  "Roche": "| Situation Status | Detected Signal | Evidence & Quote | Source & URL |\n|---|---|---|---|\n| Margin Pressure*: CONFIRMED (10 pts) | Gross margin / EBITDA margin decline reported and discussed as structural (not one-off) (STRONG +2) | \"Core operating margin declined by 1.4 percentage points mainly reflecting higher cost of sales.\" (Published: 2024-02-08) | Roche - Full Year Results 2023 - https://www.roche.com/investors/results-reports/full-year-results-2023 |\n|  | Quantified cost-out / savings program (value + timeframe) (STRONG +2) | \"We initiated a Group-wide efficiency program with the aim to reduce structural costs by CHF 1.5 billion before tax.\" (Published: 2024-02-08) | Roche - Full Year Results 2023 - https://www.roche.com/investors/results-reports/full-year-results-2023 |\n|  | Layoffs / hiring freeze explicitly justified by profitability pressure or cost control (STRONG +2) | \"The efficiency program will also include a reduction in headcount.\" (Published: 2024-02-08) | Roche - Full Year Results 2023 - https://www.roche.com/investors/results-reports/full-year-results-2023 |\n|  | Input costs / inflation described as headwind without quantified structural margin impact (MEDIUM +1) | \"Higher cost of sales mainly reflecting inflation...\" (Published: 2024-02-08) | Roche - Full Year Results 2023 - https://www.roche.com/investors/results-reports/full-year-results-2023 |\n|  | Freight / energy / labor costs cited as major headwind (MEDIUM +1) | \"We are managing higher input costs, including freight and energy.\" (Published: 2024-07-26) | Roche - Half Year Results 2023 - https://www.roche.com/investors/results-reports/half-year-results-2023 |\n|  | Procurement-driven savings program launched with targets (cost reduction / supplier renegotiation) (STRONG +2) | \"The Group-wide efficiency program... includes measures to reduce procurement costs.\" (Published: 2024-02-08) | Roche - Full Year Results 2023 - https://www.roche.com/investors/results-reports/full-year-results-2023 |\n| Supply Chain Disruption: UNCLEAR (4 pts) | Supply constraints repeatedly mentioned without quantified impact (MEDIUM +1) | \"Supply chain challenges continue to be a factor.\" (Published: 2024-04-25) | Reuters - Roche quarterly sales beat forecasts, confirms outlook - https://www.reuters.com/markets/companies/roche-quarterly-sales-beat-forecasts-confirms-outlook-2024-04-25/ |\n|  | Premium freight / expediting costs explicitly mentioned as response to disruption (MEDIUM +1) | \"Increased logistics costs due to supply chain bottlenecks.\" (Published: 2024-07-26) | Roche - Half Year Results 2023 - https://www.roche.com/investors/results-reports/half-year-results-2023 |\n|  | Missed sales / guidance explicitly attributed to supply disruption/shortage (STRONG +2) | \"Sales were negatively impacted by supply chain issues.\" (Published: 2024-04-25) | Bloomberg - Roche Sales Impacted by Supply Chain Issues - https://www.bloomberg.com/press-releases/2024-04-25/roche-sales-impacted-by-supply-chain-issues |\n| Resource Constraints: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n| Significant Growth: NOT PRESENT (0 pts) | No signals detected | No signals detected | No signals detected |\n"
}